Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark R Litzow

Showing results (251-260 of 457) with videos related to

Pageof 46
Sort By:
Blood Cancer Journal|February 14, 2018
Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblastsAbhishek A Mangaonkar, Terra L Lasho, Christy M Finke, et al.
British Journal of Haematology|August 4, 2021
De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive casesKebede H Begna, Jaya Kittur, Jennifer Yui, et al.
British Journal of Haematology|May 5, 2023
The clinical and molecular spectrum of ETV6 mutated myeloid neoplasmsMark Gurney, Ismahene Chekkaf, Anmol Baranwal, et al.
Cell Death & Disease|November 7, 2025
The RNA N<sup>6</sup>-methyladenosine methylome coordinates long non-coding RNAs to mediate cancer drug resistance by activating PI3K signalingYanhong Tan, Changli Zhou, Sicheng Bian, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 19, 2016
Health-Related Quality of Life among Older Related Hematopoietic Stem Cell Donors (>60 Years) Is Equivalent to That of Younger Related Donors (18 to 60 Years): A Related Donor Safety StudyGalen E Switzer, Jessica Bruce, Deidre M Kiefer, et al.
Leukemia Research|November 13, 2021
Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trialSelina M Luger, Victoria X Wang, Jacob M Rowe, et al.
Leukemia & Lymphoma|October 24, 2012
Comparison of complication rates of Hickman(®) catheters versus peripherally inserted central catheters in patients with acute myeloid leukemia undergoing induction chemotherapyMing Y Lim, Aref Al-Kali, Aneel A Ashrani, et al.
American Journal of Hematology|March 26, 2022
Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survivalTalha Badar, Ehab Atallah, Rory M Shallis, et al.
Leukemia|February 22, 2023
Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)Talha Badar, Ehab Atallah, Rory Shallis, et al.
Haematologica|December 15, 2022
Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blastphase myeloproliferative neoplasmNaseema Gangat, Rimal Ilyas, Kristen McCullough, et al.
Pageof 46

Showing results (251-260 of 457) with videos related to

Sort By:
Pageof 46
Blood Cancer Journal|February 14, 2018
Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblastsAbhishek A Mangaonkar, Terra L Lasho, Christy M Finke, et al.
British Journal of Haematology|August 4, 2021
De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive casesKebede H Begna, Jaya Kittur, Jennifer Yui, et al.
British Journal of Haematology|May 5, 2023
The clinical and molecular spectrum of ETV6 mutated myeloid neoplasmsMark Gurney, Ismahene Chekkaf, Anmol Baranwal, et al.
Cell Death & Disease|November 7, 2025
The RNA N<sup>6</sup>-methyladenosine methylome coordinates long non-coding RNAs to mediate cancer drug resistance by activating PI3K signalingYanhong Tan, Changli Zhou, Sicheng Bian, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 19, 2016
Health-Related Quality of Life among Older Related Hematopoietic Stem Cell Donors (>60 Years) Is Equivalent to That of Younger Related Donors (18 to 60 Years): A Related Donor Safety StudyGalen E Switzer, Jessica Bruce, Deidre M Kiefer, et al.
Leukemia Research|November 13, 2021
Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trialSelina M Luger, Victoria X Wang, Jacob M Rowe, et al.
Leukemia & Lymphoma|October 24, 2012
Comparison of complication rates of Hickman(®) catheters versus peripherally inserted central catheters in patients with acute myeloid leukemia undergoing induction chemotherapyMing Y Lim, Aref Al-Kali, Aneel A Ashrani, et al.
American Journal of Hematology|March 26, 2022
Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survivalTalha Badar, Ehab Atallah, Rory M Shallis, et al.
Leukemia|February 22, 2023
Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)Talha Badar, Ehab Atallah, Rory Shallis, et al.
Haematologica|December 15, 2022
Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blastphase myeloproliferative neoplasmNaseema Gangat, Rimal Ilyas, Kristen McCullough, et al.
Pageof 46